

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated Friday, June 18, 2021 (the “**Prospectus**”) of HUTCHMED (China) Limited (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended from time to time, (the “**U.S. Securities Act**”)) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act. Any public offering of the Company’s securities outside of the public offering in Hong Kong will be made (i) pursuant to the shelf registration statement on Form F-3ASR that was filed with the U.S. Securities and Commission and became effective on April 6, 2020 and (ii) in respect of securities to be sold to certain cornerstone investors, in reliance on Rule 901 of Regulation S under the U.S. Securities Act pursuant to another exemption from the registration requirements of the U.S. Securities Act, as described in the section headed “Structure of the Global Offering – The International Offering” in the Prospectus.

No prospectus required for the purposes of Regulation (EU) 2017/1129 (“**EU Prospectus Regulation**”) or Regulation (EU) 2017/1129 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018) (“**UK Prospectus Regulation**”) or admission document (as defined in the AIM Rules for Companies published by the London Stock Exchange plc) will be made available in connection with the matters contained in this announcement. In any member state of the European Economic Area, this announcement is only addressed to and directed at qualified investors in that member state as defined in article 2(e) of the EU Prospectus Regulation.

This announcement, insofar as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the U.K. Financial Services and Markets Act 2000, as amended) in connection with the securities which are the subject of the Global Offering, is being directed only at (i) persons who are outside the United Kingdom or (ii) if in the United Kingdom, persons who are qualified investors as defined in article 2(e) of the UK Prospectus Regulation who also (a) have professional experience in matters relating to investments who fall within Article 19(5) (investment professionals) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “**Order**”) or (b) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Order; or (iii) any other person to whom it may lawfully be communicated (all such persons in (i) to (iii) together being referred to as “**specified persons**”). This announcement is directed only at specified persons and must not be acted on or relied on in the United Kingdom by persons who are not specified persons. Any investment or investment activity to which this announcement relates is available only to specified persons and will be engaged in only with specified persons.

In connection with the Global Offering, Morgan Stanley Asia Limited, as stabilizing manager (the “**Stabilizing Manager**”) (or any person acting for it), on behalf of the Underwriters, may over-allocate or effect transactions on the Stock Exchange with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or any person acting for it) to conduct any such stabilizing action, which, if taken, will be done at the absolute discretion of the Stabilizing Manager (or any person acting for it) and in what the Stabilizing Manager reasonably regards as the best interest of the Company and may be discontinued at any time. Any such stabilizing action is required to be brought to an end on the 30th day after the last day for lodging applications under the Hong Kong Public Offering.

*Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong), Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018) and Regulation M under the U.S. Securities Exchange Act of 1934, as amended. Further details are set forth in the section “Structure of the Global Offering” in the Prospectus.*

*Potential investors should be aware that no stabilizing action can be taken on the Stock Exchange to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Friday, July 23, 2021 being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.*

*In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters. Pursuant to the Over-allotment Option, the International Underwriters will have the right, exercisable at any time from the Listing Date to 30 days after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Offering, if any.*



**HUTCHMED (China) Limited**

**和黃醫藥(中國)有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 13)**

## **GLOBAL OFFERING**

<b>Number of Offer Shares under the Global Offering</b>	<b>:</b>	<b>104,000,000 Shares (subject to the Over-allotment Option)</b>
<b>Number of Hong Kong Offer Shares</b>	<b>:</b>	<b>13,000,000 Shares</b>
<b>Number of International Offer Shares</b>	<b>:</b>	<b>91,000,000 Shares (subject to the Over-allotment Option)</b>
<b>Final Offer Price</b>	<b>:</b>	<b>HK\$40.10 per Offer Share plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)</b>
<b>Nominal Value</b>	<b>:</b>	<b>US\$0.10 per Share</b>
<b>Stock code</b>	<b>:</b>	<b>13</b>

*Joint Sponsors, Joint Global Coordinators and Joint Bookrunners*

**Morgan Stanley      Jefferies       CICC 中金公司**

*Joint Global Coordinators and Joint Bookrunners*

**CREDIT SUISSE** 

 **HSBC**

*Joint Bookrunners*

 **MACQUARIE**

**Deutsche Bank** 

 **BOC INTERNATIONAL**

 **招銀國際**  
CMB INTERNATIONAL

**CMS**  **招商證券國際**

## ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS

### SUMMARY

#### OFFER PRICE

- The Company refers to its announcement dated June 23, 2021 in which it announced that the Offer Price of the Offer Shares had been determined at HK\$40.10 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

#### NET PROCEEDS OF THE GLOBAL OFFERING

- Based on the Offer Price of HK\$40.10 per Offer Share, the net proceeds of the Global Offering to be received by the Company, after deduction of the underwriting commissions and other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$3,950 million. The Company intends to apply such net proceeds in accordance with the purposes as set out in the section headed “*Net Proceeds from the Global Offering*” in this announcement.
- If the Over-allotment Option is exercised in full, additional net proceeds of approximately HK\$603.0 million would be received for the 15,600,000 Shares to be issued upon the exercise of the Over-allotment Option.

#### APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED

##### Hong Kong Public Offering

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been over-subscribed. A total of 21,124 valid applications have been received pursuant to the Hong Kong Public Offering through the **White Form eIPO** service and through the **CCASS EIPO** service for a total of 67,994,500 Hong Kong Offer Shares, representing approximately 5.23 times of the total number of 13,000,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the over-subscription in the Hong Kong Public Offering represents less than 12.5 times of the number of the Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedure as disclosed in the section headed “*Structure of the Global Offering – The Hong Kong Public Offering – Reallocation and Clawback*” in the Prospectus has not been applied.
- The final number of Offer Shares under the Hong Kong Public Offering is 13,000,000 Offer Shares, representing 12.5% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) and have been allocated to 12,992 successful applicants under the Hong Kong Public Offering.

## INTERNATIONAL OFFERING

- The Offer Shares initially offered under the International Offering were over-subscribed, with the total number of International Offer Shares subscribed under the International Offering representing approximately 5.0 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 91,000,000 Shares, representing approximately 87.5% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 15,600,000 Offer Shares in the International Offering.
- The total number of placees under the International Offering is 105. A total number of 50 placees have been allotted five board lots of Shares or less, representing approximately 47.62% of the total number of placees under the International Offering. These placees have been allotted one board lot each of 500 Shares, and, in total, 25,000 Shares, representing approximately 0.0275% of the Offer Shares available under the International Offering (before any exercise of the Over-allotment Option) and 0.0240% of the Offer Shares under the Global Offering (before any exercise of the Over-allotment Option).

### Over-allotment Option

- In connection with the Global Offering, the Over-allotment Option has been granted to the International Underwriters, exercisable by the Joint Global Coordinators on behalf of the International Underwriters, within 30 days from the last day for lodging applications under the Hong Kong Public Offering (the last day for exercise of the Over-allotment Option being Friday, July 23, 2021) to require the Company to allot and issue up to an aggregate of 15,600,000 additional Offer Shares, representing not more than 15% of the Offer Shares initially available under the Global Offering, at the Offer Price, to cover over-allocations in the International Offering, if any. There has been an over-allocation of 15,600,000 Offer Shares in the International Offering, and the Stabilizing Manager (or any person acting for it) may cover such over-allocations by, among other methods, exercising the Over-allotment Option in full or in part, by using Shares purchased by the Stabilizing Manager (or any person acting for it) in the secondary market at prices that do not exceed the Offer Price or through the Stock Borrowing Agreement as detailed in the Prospectus or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) and the website of the Company at [www.hutch-med.com](http://www.hutch-med.com). As of the date of this announcement, the Over-allotment Option has not been exercised.

## Cornerstone Investors

- Based on the Offer Price of HK\$40.10 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) and pursuant to the cornerstone investment agreements with the Cornerstone Investors as set out in the section headed “*Cornerstone Investors*” in the Prospectus, the Cornerstone Investors have subscribed for a total of 63,215,500 Offer Shares, representing (a) approximately 7.5% of the Company’s issued share capital immediately upon completion of the Global Offering and (b) 60.8% of the number of Offer Shares under the Global Offering, in each case assuming the Over-allotment Option is not exercised and without taking into account the Shares to be issued by the Company pursuant to the share options granted under the Hutchmed Option Schemes or the exercise of the Warrant. For details of the information about the identities of the Cornerstone Investors, the number of Offer Shares subscribed for by them, the confirmation about their independence and the lock-up arrangement, please refer to the section headed “International Offering – Cornerstone Investors” below.
- The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 5(1) of Appendix 6 to the Listing Rules to permit the Company to allocate Offer Shares in the International Offering to CICC Grandeur (Xiamen) Equity Investment Fund Partnership (L.P.), which is a connected client of China International Capital Corporation Hong Kong Securities Limited, one of the Joint Sponsors, Joint Global Coordinators and Joint Bookrunners, within the meaning of the Placing Guidelines, as a Cornerstone Investor.
- Certain Cornerstone Investors, namely Canada Pension Plan Investment Board and General Atlantic Singapore HCM Pte. Ltd., are existing Shareholders. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, its consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate the Offer Shares to Canada Pension Plan Investment Board and General Atlantic Singapore HCM Pte. Ltd. as Cornerstone Investors. Please refer to the section headed “*Waivers and Exemptions – Waiver in relation to restrictions on existing Shareholders to subscribe for Shares – Private Placement Investors*” in the Prospectus for further details.

## Placees

- In addition to placing to CICC Grandeur (Xiamen) Equity Investment Fund Partnership (L.P.) under the cornerstone investment agreement, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares under the International Offering to the placees set out in the section headed “*International Offering – Placees*” in this announcement.
- In addition, 6,300,000 Shares were allocated to CII, an existing Shareholder of the Company, in compliance with all the conditions under the waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and paragraph 5(2) of the Placing Guidelines granted by the Stock Exchange. Please refer to the section headed “*Waivers and Exemptions – Waiver in relation to restrictions on existing Shareholders to subscribe for Shares – Other Non-connected Existing Shareholders*” in the Prospectus for further details.



## LOCK-UP UNDERTAKINGS

- The Company, the Controlling Shareholders, certain existing Shareholders, the Directors, certain members of the senior management of the Company and the Cornerstone Investors are subject to certain lock-up undertakings as set out in the section headed “*Lock-up Undertakings*” in this announcement.

## RESULTS OF ALLOCATIONS

- The level of indications of interests in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will be published on Tuesday, June 29, 2021 in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese) and on the websites of the Company at [www.hutch-med.com](http://www.hutch-med.com) and the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk).
- The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **White Form eIPO** service or through the **CCASS EIPO** service, including the Hong Kong identity card numbers, passport numbers, Hong Kong business registration numbers or beneficial owner identification codes of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:
  - in the announcement to be posted on the website of the Company at [www.hutch-med.com](http://www.hutch-med.com) and the Stock Exchange’s website at <http://www.hkexnews.hk>, respectively, by no later than 9:00 a.m. on Tuesday, June 29, 2021;
  - from the designated results of allocations website at [www.iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a “search by ID function” on a 24 hour basis from 8:00 a.m. on Tuesday, June 29, 2021 to 12:00 midnight on Monday, July 5, 2021; and
  - from the allocation results telephone enquiry by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Tuesday, June 29, 2021, Wednesday, June 30, 2021, Friday, July 2, 2021 and Monday, July 5, 2021.

## DISPATCH/COLLECTION OF SHARE CERTIFICATES/E-REFUND PAYMENT INSTRUCTIONS/REFUND CHEQUES

- Applicants who have applied for 1,000,000 Hong Kong Offer Shares or more through the **White Form eIPO** service and who have been successfully or partially successfully allocated Hong Kong Offer Shares may collect Share certificate(s) (where applicable) in person from the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Hong Kong from 9:00 a.m. to 1:00 p.m. on Tuesday, June 29, 2021 or any other place or date notified by the Company in the newspapers as the date of dispatch or collection of Share certificates.

- Share certificates for Hong Kong Offer Shares allotted to applicants who applied through the **White Form eIPO** service, which are either not eligible for personal collection, or which are eligible but are not collected in person within the time specified for collection, are expected to be dispatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on or before Tuesday, June 29, 2021.
- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC will have their Share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant who gave **electronic application instructions** on their behalf on Tuesday, June 29, 2021.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.
- Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS should check the announcement made by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Tuesday, June 29, 2021 or such other date as shall be determined by HKSCC or HKSCC Nominees. Applicants who applied as a CCASS Investor Participant may also check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies (if any) payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time). Immediately after the crediting of the Hong Kong Offer Shares to the CCASS Investor Participants stock accounts and the credit of refund monies to the CCASS Investor Participants bank accounts, HKSCC will also make available to the CCASS Investor Participants an activity statement showing the amount of Hong Kong Offer Shares credited to their CCASS Investor Participant stock accounts and the refund amount credited to their respective designated bank accounts (if any).
- For applicants who have applied for the Hong Kong Offer Shares through the **White Form eIPO** service and paid the application monies through a single bank account, refund monies (if any) will be dispatched to their application payment bank account in the form of e-Refund payment instructions on or before Tuesday, June 29, 2021. For applicants who have applied for the Hong Kong Offer Shares through the **White Form eIPO** service and paid the application monies through multiple bank accounts, refund monies (if any) will be dispatched to the addresses specified on the **White Form eIPO** applications in the form of refund cheque(s) by ordinary post and at their own risk on or before Tuesday, June 29, 2021.
- Refund monies (if any) for applicants who applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their broker or custodian on Tuesday, June 29, 2021.



- Share certificates will only become valid certificates of title at 8:00 a.m. on Wednesday, June 30, 2021 provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination as described in the paragraph headed “*Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination*” in the Prospectus has not been exercised.
- The Company will not issue any temporary documents of title in respect of the Hong Kong Offer Shares. No receipt will be issued for application monies received.

### **Commencement of Dealings in the Shares**

- Assuming that the Global Offering becomes unconditional in all aspects at or before 8:00 a.m. on Wednesday, June 30, 2021, dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, June 30, 2021. The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 13.

## **OFFER PRICE**

The Company refers to its announcement dated June 23, 2021 in which it announced that the Offer Price of the Offer Shares had been determined at HK\$40.10 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

## **NET PROCEEDS OF THE GLOBAL OFFERING**

Based on the Offer Price of HK\$40.10 per Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting commissions and other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$3,950 million (assuming the Over-allotment Option is not exercised). The Company currently intends to apply such net proceeds for the following purposes:

- approximately HK\$1,975 million (or approximately 50% of the net proceeds) to advance the Company’s late-stage clinical programs for savolitinib, surufatinib, fruquintinib, HMPL-689 and HMPL-523 through registration trials and potential NDA submissions;
- approximately HK\$395 million (or approximately 10% of the net proceeds) will be used to support further proof-of-concept studies and fund continued expansion of the Company’s product portfolio in cancer and immunological diseases through internal research, including the development cost of early-clinical and preclinical-stage pipeline drug candidates;
- approximately HK\$790 million (or approximately 20% of the net proceeds) will be used to further strengthen the Company’s integrated capabilities across commercialization, clinical and regulatory and manufacturing;
- approximately HK\$593 million (or approximately 15% of the net proceeds) to fund potential global business development and strategic acquisition opportunities to complement the Company’s internal research and development activities;
- Approximately HK\$197 million (or approximately 5% of the net proceeds) for working capital, expanding internal capabilities globally and in China, and general corporate purposes.

If the Over-allotment Option is exercised in full, additional net proceeds of approximately HK\$603.0 million would be received for the 15,600,000 Shares to be issued upon the exercise of the Over-allotment Option.

For further information, please refer to the section headed “*Future Plans and Use of Proceeds - Use of Proceeds*” in the Prospectus.

## **APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED**

### **The Hong Kong Public Offering**

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been over-subscribed. A total of 21,124 valid applications have been received pursuant to the Hong Kong Public Offering through the **White Form eIPO** service and through the **CCASS EIPO** service for a total of 67,994,500 Hong Kong Offer Shares, representing approximately 5.23 times of the total number of 13,000,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 21,077 valid applications in respect of a total of 42,344,500 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$45.00 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) of HK\$5 million or less, representing approximately 6.51 times of the 6,500,000 Hong Kong Offer Shares initially comprised in Pool A of the Hong Kong Public Offering; and
- 47 valid applications in respect of a total of 25,650,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$45.00 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%) of more than HK\$5 million, representing approximately 3.95 times of the 6,500,000 Hong Kong Offer Shares initially comprised in Pool B of the Hong Kong Public Offering.

32 multiple or suspected multiple applications have been identified and rejected. No applications have been rejected due to dishonored payments or invalid application. No application for more than 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering (that is, more than 6,500,000 Hong Kong Offer Shares) has been identified.

As the over-subscription in the Hong Kong Public Offering represents less than 12.5 times of the Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedure as disclosed in the section headed “*Structure of the Global Offering – The Hong Kong Public Offering – Reallocation and Clawback*” in the Prospectus has not been applied. The final number of Offer Shares under the Hong Kong Public Offering is 13,000,000 Offer Shares, representing 12.5% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option) and have been allocated to 12,992 successful applicants under the Hong Kong Public Offering.

The Hong Kong Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the paragraph headed “*Basis of allotment under the Hong Kong Public Offering*” below.

## INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering were over-subscribed, with the total number of International Offer Shares subscribed under the International Offering representing approximately 5.0 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 91,000,000 Shares, representing approximately 87.5% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 15,600,000 Offer Shares in the International Offering. The total number of placees under the International Offering is 105. A total number of 50 placees have been allotted five board lots of Shares or less, representing approximately 47.62% of the total number of placees under the International Offering. These placees have been allotted one board lot each of 500 Shares, and, in total, 25,000 Shares, representing approximately 0.0275% of the Offer Shares available under the International Offering (before any exercise of the Over-allotment Option) and 0.0240% of the Offer Shares under the Global Offering (before any exercise of the Over-allotment Option).

### Cornerstone Investors

Based on the Offer Price of HK\$40.10 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) and pursuant to the relevant cornerstone investment agreements as disclosed in the section headed “*Cornerstone Investors*” in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investors is determined as set out below:

Cornerstone Investors	Number of Offer Shares Subscribed For	Number of Shares to be Held Upon Listing	Offer Shares Subscribed for as percentage of Offer Shares in the Global Offering <sup>(1)</sup>	Offer Shares subscribed for as percentage of total issued share capital immediately following the completion of the Global Offering <sup>(1)</sup>	Total Shares to be held upon Listing as Percentage of total issued share capital immediately following the completion of the Global Offering <sup>(1)</sup>
CA Fern Parent	40,847,500	40,847,500	39.28%	4.81%	4.81%
Canada Pension Plan Investment Board	9,725,500	26,883,270	9.35%	1.15%	3.17%
General Atlantic Singapore HCM Pte. Ltd.	5,835,000	25,835,000	5.61%	0.69%	3.04%
HBM Healthcare Investments (Cayman) Ltd.	3,890,000	3,890,000	3.74%	0.46%	0.46%
CICC Grandeur (Xiamen) Equity Investment Fund Partnership (L.P.)	2,917,500	2,917,500	2.81%	0.34%	0.34%
<b>Total</b>	<b>63,215,500</b>	<b>100,373,270</b>	<b>60.78%</b>	<b>7.45%</b>	<b>11.83%</b>

Note:

- (1) Assuming that the Over-allotment Option is not exercised and without taking into account any Shares which may be issued by the Company pursuant to the share options granted under the Hutchmed Option Schemes or the exercise of the Warrant.

The Cornerstone Investments will form part of the International Offering and the Cornerstone Investors will not subscribe for any Offer Shares under the Global Offering (other than pursuant to the cornerstone investment agreements). The Offer Shares to be delivered to each of the Cornerstone Investors pursuant to the relevant cornerstone investment agreement will rank *pari passu* with all other Shares then in issue and to be listed on the Stock Exchange and will count towards the public float of the Shares.

CICC Grandeur (Xiamen) Equity Investment Fund Partnership (L.P.) is a connected client of China International Capital Corporation Hong Kong Securities Limited, one of the Joint Sponsors, Joint Global Coordinators and Joint Bookrunners of the Global Offering. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, its consent under paragraph 5(1) of Appendix 6 to the Listing Rules (the “**Placing Guidelines**”) to permit CICC Grandeur (Xiamen) Equity Investment Fund Partnership (L.P.) to participate in the Global Offering as a cornerstone investor subject to certain conditions. Please refer to the section headed “*Waivers and Exemptions – Waiver in relation to Allocation of Offer Shares to a Connected Client*” in the Prospectus for further details.

Certain Cornerstone Investors, namely Canada Pension Plan Investment Board and General Atlantic Singapore HCM Pte. Ltd., are existing Shareholders. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, its consent under paragraph 5(2) of the Placing Guidelines to permit the Company to allocate the Offer Shares to Canada Pension Plan Investment Board and General Atlantic Singapore HCM Pte. Ltd. Please refer to the section headed “*Waivers and Exemptions – Waiver in relation to restrictions on existing Shareholders to subscribe for Shares – Private Placement Investors*” in the Prospectus for further details.

To the best knowledge of the Company, (i) save as disclosed in the section headed “*Waivers and Exemptions*” in the Prospectus, each Cornerstone Investor is an independent third party, is not a connected person of the Company and is not an existing Shareholder; (ii) none of the Cornerstone Investors is accustomed to taking instructions from the Company or the Directors, the chief executives or the substantial Shareholders of the Company or of any of its subsidiaries or a close associate of any of them in relation to the acquisition, disposal, voting or other disposition of securities of the issuer; and (iii) none of the subscription of the relevant Offer Shares by any of the Cornerstone Investors is financed by the Company or the Directors, the chief executives or the substantial Shareholders of the Company or of any of its subsidiaries or a close associate of any of them. Immediately following the completion of the Global Offering, none of the Cornerstone Investors will become a substantial shareholder of the Company, and none of the Cornerstone Investors will have any representation on the Board. There are no side arrangements between the Company and the Cornerstone Investors or any benefit, direct or indirect, conferred on the Cornerstone Investors by virtue of or in relation to the Cornerstone Investments other than the guaranteed allocation of the relevant Offer Shares at the Offer Price, save with respect to certain existing rights of Canada Pension Plan Investment Board and General Atlantic Singapore HCM Pte. Ltd. under the relevant subscription agreements for the private placements conducted in 2020, further details of which are set out in “*History and Corporate Structure – Private Placements*” in the Prospectus.

Each Cornerstone Investor has agreed that without the prior written consent of the Company, the Joint Sponsors and the Joint Global Coordinators, it will not, whether directly or indirectly, at any time during the period of six months following the Listing Date, dispose of (as defined in the relevant cornerstone investment agreement) any of the Shares subscribed by it pursuant to the relevant cornerstone investment agreement and any other securities of the Company which are derived therefrom (the “**Relevant Shares**”) or any interest in any company or entity holding any of the Relevant Shares. As set out in the relevant cornerstone investment agreement, each Cornerstone Investor may transfer the Relevant Shares in certain limited circumstances of (i) a transfer to a wholly-owned subsidiary of such Cornerstone Investor, provided that prior to such transfer, such wholly-owned subsidiary undertakes to be bound by such Cornerstone Investor’s obligations under the relevant cornerstone investment agreement and be subject to the restrictions on disposal of Relevant Shares imposed on such Cornerstone Investor, or (ii) as security for external debt financing, provided that the Cornerstone Investor procures the lender to be subject to the same restrictions on disposal as provided in the cornerstone investment agreement.

Please refer to the section headed “*Cornerstone Investors*” in the Prospectus for further details.

## Placees

In addition to placing to CICC Grandeur (Xiamen) Equity Investment Fund Partnership (L.P.) under the cornerstone investment agreement described above, certain Offer Shares were placed to connected clients of UBS Securities Asia Ltd., a distributor within the meaning of the Placing Guidelines for equity securities as set out in Appendix 6 to the Listing Rules, details of which are set out below:

Placee	Connected Distributor	Relationship with Connected Distributor	Number of Offer Shares Placed	Approximate percentage of Offer Shares in the Global Offering <sup>(1)</sup>	Approximate percentage of the total issued share capital immediately following completion of the Global Offering <sup>(1)</sup>
UBS Asset Management (Singapore) Limited	UBS Securities Asia Ltd.	UBS Asset Management (Singapore) Limited and UBS Securities Asia Ltd. are in the same group of companies under UBS AG.	3,984,000	3.83%	0.47%
UBS O’Connor LLC	UBS Securities Asia Ltd.	UBS O’Connor LLC and UBS Securities Asia Ltd. are in the same group of companies under UBS AG.	235,000	0.23%	0.03%

Note:

- (1) Assuming that the Over-allotment Option is not exercised and without taking into account any Shares which may be issued by the Company pursuant to the share options granted under the Hutchmed Option Schemes or the exercise of the Warrant (as the case may be).



The Company has applied to the Stock Exchange for, and the Stock Exchange has granted the Company, consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to the above placees. The Shares placed to the above connected clients are held by the connected clients on behalf of independent third parties and are in compliance with all the conditions under the consent granted by the Stock Exchange.

Furthermore, 6,300,000 Shares were allocated to Capital International Investors (“CII”), an existing Shareholder of the Company. Prior to the completion of the Global Offering, CII is interested in approximately 7.11% of the Company’s issued share capital. After taking into account the 6,300,000 Offer Shares allocated to CII (representing approximately 6.92% of the Offer Shares under the International Offering), CII will be interested in approximately 6.98% of the Company’s issued share capital immediately upon the completion of the Global Offering (assuming the Over-allotment Option is not exercised). The Offer Shares placed to CII are in compliance with all the conditions under the waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules and paragraph 5(2) of the Placing Guidelines granted by the Stock Exchange. Please refer to the section headed “*Waivers and Exemptions – Waiver in relation to restrictions on existing Shareholders to subscribe for Shares – Other Non-connected Existing Shareholders*” in the Prospectus for further details.

Save as disclosed above and in the Prospectus, to the best knowledge, information and belief of the Directors, no Offer Shares placed by or through the Joint Sponsors, Joint Global Coordinators, the Joint Bookrunners or the Underwriters under the Global Offering have been placed to (i) any core connected persons (as defined in the Listing Rules), or (ii) save for CII, any of the existing Shareholders interested in more than 5% of the Company’s voting rights immediately before the Listing, whether in their own names or through nominees. Save as disclosed above and in the Prospectus, the International Offering is in compliance with the Placing Guidelines.

The Directors confirm that (a) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (b) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company immediately after the Global Offering; (c) the number of Shares in public hands will satisfy the minimum percentage as required by Rule 8.08(1) of the Listing Rules; (d) the three largest public shareholders of the Company do not hold more than 50% of the Shares in public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (e) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.



The Directors confirm that, to the best of their knowledge, information and belief, none of the Offer Shares subscribed by the placees and the public has been financed directly or indirectly by any of the Directors, chief executive of the Company, substantial Shareholders and controlling Shareholders of the Company or any of its subsidiaries or their respective close associates, and none of the placees and the public who has purchased the Offer Shares is accustomed to taking instructions from any of the Directors, chief executive of the Company, substantial Shareholders and controlling Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

### **Over-allotment Option**

In connection with the Global Offering, the Company has granted the right to the International Underwriters, exercisable by the Joint Global Coordinators (on behalf of the International Underwriters), at any time from the Listing Date until Friday, July 23, 2021, the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue up to an aggregate of 15,600,000 Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price under the International Offering to cover over-allocations in the International Offering. There has been an over-allocation of 15,600,000 Shares in the International Offering. The Stabilizing Manager (or any person acting for it) may cover such over-allocations by, among other methods, exercising the Over-allotment Option in full or in part, by using Shares purchased by the Stabilizing Manager (or any person acting for it) in the secondary market at prices that do not exceed the Offer Price or through the Stock Borrowing Agreement as detailed in the Prospectus or a combination of these means. If the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) and the website of the Company at [www.hutch-med.com](http://www.hutch-med.com). As of the date of this announcement, the Over-allotment Option has not been exercised.

## LOCK-UP UNDERTAKINGS

The Company, the Controlling Shareholders, certain existing Shareholders, the Directors, certain members of the senior management of the Company and the Cornerstone Investors have provided certain lock-up undertakings (the “**Lock-up Undertakings**”) in respect of the Shares. The major terms of the Lock-up Undertakings are set out as follows:

Name	Number of Shares subject to the Lock-up Undertakings after Listing <sup>(1)</sup>	Approximate % of the total issued share capital of the Company following the completion of the Global Offering which are subject to the Lock-up Undertakings after Listing <sup>(1)</sup>	Last day of the lock-up period
<b>The Company</b> (subject to lock-up obligations pursuant to the Listing Rules, the Hong Kong Underwriting Agreement and the International Underwriting Agreement)	N/A	N/A	December 30, 2021 <sup>(2)</sup>
<b>All Controlling Shareholders</b> <sup>(6)</sup> (subject to lock-up obligations pursuant to the Listing Rules and lock-up undertakings)	332,502,740	39.19%	December 30, 2021 (First Six-Month Period) June 30, 2022 (Second Six-Month Period) <sup>(3)</sup>
<b>Certain Existing Shareholders</b> <sup>(7)</sup> (subject to lock-up obligations pursuant to relevant subscription agreements)			
General Atlantic Singapore HCM Pte. Ltd.			
– Shares	20,000,000	2.36%	July 2, 2021
– Warrant <sup>(8)</sup>	16,666,670	1.96%	July 2, 2021
Canada Pension Plan Investment Board	16,666,670	1.96%	November 26, 2021
Pachytene Limited (Baring)	16,393,445	1.93%	April 9, 2022
<b>Directors and Certain Members of Senior Management</b> <sup>(9)</sup> (subject to lock-up obligations pursuant to separate lock-up undertakings)	18,200,695	2.15%	September 30, 2021 <sup>(4)</sup>
<b>Cornerstone Investors</b> (subject to lock-up obligations pursuant to the relevant cornerstone investment agreements)	63,215,500	7.45%	December 30, 2021 <sup>(5)</sup>

Notes:

- (1) Assuming the Over-allotment Option is not exercised and without taking into account any Shares which may be issued by the Company pursuant to the share options granted under the Hutchmed Option Schemes or the exercise of the Warrant.

- (2) The Company may issue Shares without any lock-up obligations after the indicated date.
- (3) The Controlling Shareholders shall not (a) dispose of any of the relevant shares in the First Six-Month Period; and (b) dispose of any of the relevant shares in the Second Six-Month Period if immediately following such disposal the Controlling Shareholders would cease to be a controlling shareholder (as defined in the Listing Rules) of the Company.
- (4) The Directors and certain members of senior management shall not dispose of the relevant shares or ADSs for a period of 90 days from the Listing Date, save for certain special circumstances.
- (5) The Cornerstone Investors shall not dispose of their respective Relevant Shares for a period of six months from the Listing Date, save for certain special circumstances.
- (6) Each of CK Hutchison Holdings Limited, CK Hutchison Global Investments Limited, Hutchison Whampoa (China) Limited and Hutchison Healthcare Holdings Limited, each being a Controlling Shareholder, is subject to lock-up obligations with respect to the Shares in respect of which it was shown by the Prospectus to be the beneficial owner.
- (7) Certain existing Shareholders, namely, General Atlantic Singapore HCM Pte. Ltd. (“**General Atlantic**”), Canada Pension Plan Investment Board and Pachytene Limited, are subject to lock-up obligations pursuant to the respective subscription agreements, as further detailed in the “*History and Corporate Structure – Private Placements*” section in the Prospectus.
- (8) The Company and General Atlantic entered into an ordinary shares subscription warrant which upon exercise entitles General Atlantic to subscribe for 16,666,670 Shares at an exercise price of US\$6.00 per Share. This Warrant is exercisable during the period from July 2, 2020 to January 3, 2022. As of the date of this announcement, this Warrant has not been exercised.
- (9) Mr. To Chi Keung, Simon as Chairman and Executive Director, Mr. Christian Lawrence Hogg, Mr. Cheng Chig Fung, Johnny and Dr. Wei-guo Su as Executive Directors, Dr. Dan Eldar and Ms. Edith Shih as Non-executive Directors, Mr. Paul Rutherford Carter, Dr. Karen Jean Ferrante, Mr. Graeme Allan Jack and Professor Mok Shu Kam Tony as Independent Non-executive Directors and Mr. Mark Lee, Dr. May Wang and Dr. Zhenping Wu as members of Senior Management.

## BASIS OF ALLOTMENT UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the section headed “*Structure of the Global Offering — Conditions of the Global Offering*” in the Prospectus, 21,124 valid applications made by the public through the **White Form eIPO** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

No. of Shares Applied for	No. of valid applications	Basis of Allotment / Ballot	Approximate percentage allotted of the total No. of Shares Applied for
<b>POOL A</b>			
500	12,570	7,542 out of 12,570 to receive 500 Shares	60.00%
1,000	3,782	2,270 out of 3,782 to receive 500 Shares	30.01%
1,500	666	400 out of 666 to receive 500 Shares	20.02%
2,000	989	595 out of 989 to receive 500 Shares	15.04%
2,500	529	319 out of 529 to receive 500 Shares	12.06%
3,000	406	248 out of 406 to receive 500 Shares	10.18%
3,500	86	53 out of 86 to receive 500 Shares	8.80%

No. of Shares Applied for	No. of valid applications	Basis of Allotment / Ballot	Approximate percentage allotted of the total No. of Shares Applied for
4,000	212	132 out of 212 to receive 500 Shares	7.78%
4,500	78	50 out of 78 to receive 500 Shares	7.12%
5,000	570	376 out of 570 to receive 500 Shares	6.60%
6,000	136	93 out of 136 to receive 500 Shares	5.70%
7,000	67	47 out of 67 to receive 500 Shares	5.01%
8,000	85	61 out of 85 to receive 500 Shares	4.49%
9,000	40	30 out of 40 to receive 500 Shares	4.17%
10,000	386	301 out of 386 to receive 500 Shares	3.90%
15,000	104	84 out of 104 to receive 500 Shares	2.69%
20,000	117	99 out of 117 to receive 500 Shares	2.12%
25,000	42	37 out of 42 to receive 500 Shares	1.76%
30,000	38	35 out of 38 to receive 500 Shares	1.54%
35,000	17	16 out of 17 to receive 500 Shares	1.34%
40,000	33	500 Shares	1.25%
45,000	14	500 Shares plus 1 out of 14 to receive additional 500 Shares	1.19%
50,000	45	500 Shares plus 8 out of 45 to receive additional 500 Shares	1.18%
60,000	14	500 Shares plus 5 out of 14 to receive additional 500 Shares	1.13%
70,000	12	500 Shares plus 6 out of 12 to receive additional 500 Shares	1.07%
80,000	9	500 Shares plus 6 out of 9 to receive additional 500 Shares	1.04%
90,000	6	500 Shares plus 5 out of 6 to receive additional 500 Shares	1.02%
100,000	24	1,000 Shares	1.00%
	<u>21,077</u>	Total number of Pool A successful applicants: 12,945	

## POOL B

150,000	24	118,500 Shares	79.00%
200,000	11	134,000 Shares	67.00%
250,000	1	145,000 Shares	58.00%
300,000	3	156,000 Shares	52.00%
400,000	1	172,000 Shares	43.00%
500,000	3	182,000 Shares	36.40%
800,000	1	201,000 Shares	25.13%
3,000,000	1	210,000 Shares	7.00%
6,500,000	2	220,000 Shares	3.38%
	<u>47</u>	Total number of Pool B successful applicants: 47	

The final number of Offer Shares comprised in the Hong Kong Public Offering is 13,000,000 Offer Shares, representing approximately 12.5% of the total number of the Offer Shares under the Global Offering (before any exercise of the Over-allotment Option).

The number of Offer Shares comprised in the International Offering is 91,000,000 Offer Shares, which were allocated in full (subject to the Over-allotment Option), representing approximately 87.5% of the total number of the Offer Shares under the Global Offering (before any exercise of the Over-allotment Option).

## RESULTS OF ALLOCATIONS

The results of allocations of the Hong Kong Offer Shares under the Hong Kong Public Offering successfully applied for through the **White Form eIPO** service or through the **CCASS EIPO** service, including the Hong Kong identity card numbers, passport numbers, Hong Kong business registration numbers or beneficial owner identification codes of successful applicants (where supplied) and the number of the Hong Kong Offer Shares successfully applied for, will be made available at the times and dates and in the manner specified below:

- in the announcement to be posted on the website of the Company at [www.hutch-med.com](http://www.hutch-med.com) and the Stock Exchange's website at <http://www.hkexnews.hk>, respectively, by no later than 9:00 a.m. on Tuesday, June 29, 2021;
- from the designated results of allocations website at [www.iporesults.com.hk](http://www.iporesults.com.hk) (alternatively: English <https://www.eipo.com.hk/en/Allotment>; Chinese <https://www.eipo.com.hk/zh-hk/Allotment>) with a "search by ID function" on a 24 hour basis from 8:00 a.m. on Tuesday, June 29, 2021 to 12:00 midnight on Monday, July 5, 2021; and
- from the allocation results telephone enquiry by calling +852 2862 8555 between 9:00 a.m. and 6:00 p.m. on Tuesday, June 29, 2021, Wednesday, June 30, 2021, Friday, July 2, 2021 and Monday, July 5, 2021.

## SHAREHOLDING CONCENTRATION ANALYSIS

The Company sets out below the analysis of shareholding concentration in the International Offering.

- subscription of Shares held by the top 1, 5, 10 and 25 of the placees out of the International Offer Shares, total Offer Shares and our total issued share capital upon Listing (without taking into account the Shares which may be issued pursuant to the share options granted under the Hutchmed Option Schemes or the exercise of the Warrant):

Placees	Subscription	Subscription as % of International Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offer Shares (assuming the Over-allotment Option is exercised in full)	Subscription as % of Offer Shares (assuming no exercise of the Over-Allotment Option)	Subscription as % of Offer Shares (assuming the Over-Allotment Option is exercised in full)	% of Total Shares Upon Listing (assuming no exercise of the Over-Allotment Option)	% of Total Shares Upon Listing (assuming the Over-Allotment Option is exercised in full)
Top 1	40,847,500	44.9%	38.3%	39.3%	34.2%	4.8%	4.7%
Top 5	72,773,000	80.0%	68.3%	70.0%	60.8%	8.6%	8.4%
Top 10	93,383,500	102.6%	87.6%	89.8%	78.1%	11.0%	10.8%
Top 25	105,168,500	115.6%	98.7%	101.1%	87.9%	12.4%	12.2%

- subscription of Shares held by the top 1, 5, 10 and 25 of the Shareholders out of the International Offer Shares, total Offer Shares and our total issued share capital upon Listing (without taking into account the Shares which may be issued pursuant to the share options granted under the Hutchmed Option Schemes or the exercise of the Warrant):

Shareholders	Subscription	Number of Shares Held Upon Listing	Subscription as % of International Offer Shares (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offer Shares (assuming the Over-allotment Option is exercised in full)	Subscription as % of Offer Shares (assuming no exercise of the Over-Allotment Option)	Subscription as % of Offer Shares (assuming the Over-Allotment Option is exercised in full)	% of Total Shares Upon Listing (assuming no exercise of the Over-Allotment Option)	% of Total Shares Upon Listing (assuming the Over-Allotment Option is exercised in full)
Top 1	0	332,502,740	0.0%	0.0%	0.0%	0.0%	39.2%	38.5%
Top 5	53,447,500	497,946,342	58.7%	50.1%	51.4%	44.7%	58.7%	57.6%
Top 10	80,808,000	619,187,722	88.8%	75.8%	77.7%	67.6%	73.0%	71.7%
Top 25	86,377,000	776,746,212	94.9%	81.0%	83.1%	72.2%	91.5%	89.9%

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in Shares.**



## DISPATCH/COLLECTION OF SHARE CERTIFICATES/E-REFUND PAYMENT INSTRUCTIONS/REFUND CHEQUES

Applicants who have applied for 1,000,000 Hong Kong Offer Shares or more through the **White Form eIPO** service and who have been successfully or partially successfully allocated Hong Kong Offer Shares may collect Share certificate(s) (where applicable) in person from the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Hong Kong from 9:00 a.m. to 1:00 p.m. on Tuesday, June 29, 2021 or any other place or date notified by the Company in the newspapers as the date of dispatch or collection of Share certificates.

Share certificates for Hong Kong Offer Shares allotted to applicants who applied through the **White Form eIPO** service, which are either not eligible for personal collection, or which are eligible but are not collected in person within the time specified for collection, are expected to be dispatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on or before Tuesday, June 29, 2021.

Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC will have their Share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant who gave **electronic application instructions** on their behalf on Tuesday, June 29, 2021.

Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.

Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS should check the announcement made by the Company and report any discrepancies to HKSCC before 5:00 p.m. on Tuesday, June 29, 2021 or such other date as shall be determined by HKSCC or HKSCC Nominees. Applicants who applied as a CCASS Investor Participant may also check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies (if any) payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC's "An Operating Guide for Investor Participants" in effect from time to time). Immediately after the crediting of the Hong Kong Offer Shares to the CCASS Investor Participants stock accounts and the credit of refund monies to the CCASS Investor Participants bank accounts, HKSCC will also make available to the CCASS Investor Participants an activity statement showing the amount of Hong Kong Offer Shares credited to their CCASS Investor Participant stock accounts and the refund amount credited to their respective designated bank accounts (if any).

For applicants who have applied for the Hong Kong Offer Shares through the **White Form eIPO** service and paid the application monies through a single bank account, refund monies (if any) will be dispatched to their application payment bank account in the form of e-Refund payment instructions on or before Tuesday, June 29, 2021. For applicants who have applied for the Hong Kong Offer Shares through the **White Form eIPO** service and paid the application monies through multiple bank accounts, refund monies (if any) will be dispatched to the addresses specified on the **White Form eIPO** applications in the form of refund cheque(s) by ordinary post and at their own risk on or before Tuesday, June 29, 2021.

Refund monies (if any) for applicants who applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their broker brokers or custodians on Tuesday, June 29, 2021.

Share certificates will only become valid certificates of title at 8:00 a.m. on Wednesday, June 30, 2021 provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination as described in the paragraph headed "*Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for termination*" in the Prospectus has not been exercised.

The Company will not issue any temporary documents of title in respect of the Hong Kong Offer Shares. No receipt will be issued for application monies received.

## **COMMENCEMENT OF DEALINGS IN THE SHARES**

Assuming that the Global Offering becomes unconditional in all aspects at or before 8:00 a.m. on Wednesday, June 30, 2021, dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, June 30, 2021. The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 13.

All times and dates in this announcement refer to Hong Kong times and dates unless otherwise stated.

By order of the Board  
**HUTCHMED (China) Limited**  
和黃醫藥(中國)有限公司  
**Edith Shih**

*Non-executive Director and Company Secretary*

Hong Kong, June 29, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Mr. To Chi Keung, Simon as Chairman and Executive Director, Mr. Christian Lawrence Hogg, Mr. Cheng Chig Fung, Johnny and Dr. Wei-guo Su as Executive Directors, Dr. Dan Eldar and Ms. Edith Shih as Non-executive Directors, Mr. Paul Rutherford Carter, Dr. Karen Jean Ferrante, Mr. Graeme Allan Jack and Professor Mok Shu Kam Tony as Independent Non-executive Directors.*

*Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).*